• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Sartorius Stedim Biotech : Information on Document Availability

    Sartorius Stedim Biotech : Information on Document Availability

  2. First-Quarter Figures: Sartorius Stedim Biotech Off to a Good Start in 2017

    First-Quarter Figures: Sartorius Stedim Biotech Off to a Good Start in 2017

  3. ASIT biotech to publish its annual financial report on Tuesday, April 25, 2017

    ASIT biotech to publish its annual financial report on Tuesday, April 25, 2017

  4. Why biotech stocks are a healthy bet in sickly broader market

    Why biotech stocks are a healthy bet in sickly broader market

  5. BioTalent Canada’s Animation to Promote Accessibility in Biotechnology Honoured with Award

    BioTalent Canada’s Animation to Promote Accessibility in Biotechnology Honoured with Award

  6. Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma

    Tiziana Life Sciences Announces Approval of a Phase II Clinical Trial Protocol for Milciclib in Patients with Hepatocellular Carcinoma

  7. Chiral Chromatography Column Market - Drivers and Forecasts by Technavio

    Chiral Chromatography Column Market - Drivers and Forecasts by Technavio

  8. Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

    Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

  9. FDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade

    FDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade

  10. Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications

    Samsung Bioepis Obtains First Drug Approval in the United States, as the U.S. Food and Drug Administration Approves RENFLEXIS™ (Infliximab-abda) Across All Eligible Indications

12345

©2017 Morningstar Advisor. All right reserved.